Bacil Pharma Limited (BOM:524516)
India
· Delayed Price · Currency is INR 50.00
+0.05 (0.10%)
At close: Mar 9, 2026
Bacil Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Other Revenue | 5.48 | - | - | - | - | - | Upgrade
|
| Revenue | 5.48 | - | - | - | - | - | Upgrade
|
| Gross Profit | 5.48 | - | - | - | - | - | Upgrade
|
| Selling, General & Admin | 0.78 | 1.38 | 0.99 | 0.86 | 0.6 | 0.52 | Upgrade
|
| Other Operating Expenses | 1.63 | 1.14 | 0.88 | 0.91 | 0.95 | 1.09 | Upgrade
|
| Operating Expenses | 2.41 | 2.53 | 1.89 | 1.8 | 1.59 | 1.67 | Upgrade
|
| Operating Income | 3.06 | -2.53 | -1.89 | -1.8 | -1.59 | -1.67 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.05 | Upgrade
|
| Interest & Investment Income | 0.83 | 0.83 | 0.3 | 0.29 | 0.58 | 0.74 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.4 | 0.4 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 4.29 | -1.31 | -1.6 | -1.52 | -1.02 | -0.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.38 | 5.38 | 1.01 | 0.5 | -0.63 | -1.42 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -36.95 | - | Upgrade
|
| Pretax Income | 9.67 | 4.08 | -0.59 | -1.02 | -38.6 | -2.4 | Upgrade
|
| Income Tax Expense | 2.3 | 0.03 | 0 | -0 | -0 | -0 | Upgrade
|
| Net Income | 7.38 | 4.04 | -0.59 | -1.02 | -38.6 | -2.39 | Upgrade
|
| Net Income to Common | 7.38 | 4.04 | -0.59 | -1.02 | -38.6 | -2.39 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 6 | 6 | 6 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 6 | 6 | 6 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | 116.22% | 6.92% | -1.47% | 1.71% | 0.99% | -0.04% | Upgrade
|
| EPS (Basic) | 0.60 | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | Upgrade
|
| EPS (Diluted) | 0.60 | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | Upgrade
|
| Free Cash Flow | - | 4.01 | -0.03 | -1.48 | -40.09 | -3.98 | Upgrade
|
| Free Cash Flow Per Share | - | 0.64 | -0.01 | -0.25 | -6.80 | -0.68 | Upgrade
|
| Gross Margin | 100.00% | - | - | - | - | - | Upgrade
|
| Operating Margin | 55.94% | - | - | - | - | - | Upgrade
|
| Profit Margin | 134.64% | - | - | - | - | - | Upgrade
|
| EBITDA | 3.06 | -2.53 | -1.87 | -1.77 | -1.55 | -1.62 | Upgrade
|
| EBITDA Margin | 55.88% | - | - | - | - | - | Upgrade
|
| D&A For EBITDA | -0 | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | Upgrade
|
| EBIT | 3.06 | -2.53 | -1.89 | -1.8 | -1.59 | -1.67 | Upgrade
|
| EBIT Margin | 55.94% | - | - | - | - | - | Upgrade
|
| Effective Tax Rate | 23.73% | 0.85% | - | - | - | - | Upgrade
|
| Revenue as Reported | 12.09 | 6.61 | 1.31 | 1.15 | 0.58 | 0.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.